![Anders Martin-Löf](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anders Martin-Löf
Director of Finance/CFO at BIOARCTIC AB
Net worth: 53 959 $ as of 30/06/2025
Profile
Anders Martin-Löf is currently serving as an Independent Director at Cantargia AB, a Director at Oncopeptides Incentive AB, a Director at Lisa Martin-Löf Konsultbyrå AB, a Director at Affibody Medical AB, and will be the Chief Financial Officer & Secretary at BioArctic AB starting in 2023.
Previously, he held the position of Chief Financial Officer & Deputy CEO at Oncopeptides AB from 2018 to 2021.
He also served as a Director of Investor Relations at Biovitrum AB, a Director at Sciencecap Stockholm AB, the CFO, Investor Relations & Press Contact at RaySearch Laboratories AB from 2014 to 2015, the Chief Financial Officer at Extenda AB, the Head of Investor Relations at Swedish Orphan Biovitrum AB from 2006 to 2007, the Chief Financial Officer at Wilson Therapeutics AB from 2015 to 2018, and the Chief Financial Officer at A3P Biomedical AB (publ).
Mr. Martin-Löf obtained his undergraduate degree from the University of Stockholm, his graduate degree from the Royal Institute of Technology, and another graduate degree from ENSIMAG.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 16/04/2025 | 2,500 ( 0% ) | 46 876 $ | 30/06/2025 | |
CANTARGIA AB 0.02% | 31/12/2023 | 50,000 ( 0.02% ) | 7 083 $ | 30/06/2025 |
Latest news about Anders Martin-Löf
Anders Martin-Löf active positions
| Companies | Position | Start |
|---|---|---|
| CANTARGIA AB | Director/Board Member | 01/01/2018 |
| BIOARCTIC AB | Director of Finance/CFO | 01/06/2023 |
Lisa Martin-Löf Konsultbyrå AB | Director/Board Member | - |
Oncopeptides Incentive AB | Director/Board Member | - |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Director/Board Member | 01/12/2021 |
Former positions of Anders Martin-Löf
| Companies | Position | End |
|---|---|---|
| ONCOPEPTIDES AB | Director of Finance/CFO | 08/11/2021 |
| WILSON THERAPEUTICS AB | Director of Finance/CFO | 01/08/2018 |
| RAYSEARCH LABORATORIES AB | Director of Finance/CFO | 02/07/2015 |
| SWEDISH ORPHAN BIOVITRUM AB | Investor Relations Contact | 01/07/2007 |
| ░░░ ░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - |
Training of Anders Martin-Löf
Royal Institute of Technology | Graduate Degree |
ENSIMAG | Graduate Degree |
University of Stockholm | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| RAYSEARCH LABORATORIES AB | Technology Services |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| CANTARGIA AB | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| BIOARCTIC AB | Health Technology |
| Private companies | 8 |
|---|---|
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
Sciencecap Stockholm AB | |
Extenda AB
 Extenda AB Information Technology ServicesTechnology Services Extenda AB develops point-of-sale technology (POS) solutions. Its product suite include transaction engine, selfscan, mobile POS, and self checkout. The firm also offers support, service and maintenance, and catalogue services. The company was founded by Peter Carlman in 1982 and is headquartered in Stockholm, Sweden. | Technology Services |
Lisa Martin-Löf Konsultbyrå AB | |
Oncopeptides Incentive AB | |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
A3P Biomedical AB (publ)
 A3P Biomedical AB (publ) Financial ConglomeratesFinance Part of A3P Biomedical AB, a3p biomedical ab is a Swedish company located in Sweden. The company's mission is to radically improve precision in prostate cancer diagnostics and treatment. | Finance |
- Stock Market
- Insiders
- Anders Martin-Löf
